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AbstrAct
Peritoneal disseminated cancer is highly treatment resistant. We here report 
the efficacy of intraperitoneal (i.p.) administration of tumor-targeting Salmonella 
typhimurium A1-R in a nude mouse model of disseminated human ovarian cancer. 
The mouse model was established by intraperitoneal injection of the human ovarian 
cancer cell line SKOV3-GFP. Seven days after implantation, mice were treated with 
S. typhimurium A1-R via intravenous (i.v.) or i.p. administration at the same dose, 
5×107 CFU, once per week. Both i.v. and i.p. treatments effected prolonged survival 
compared with the untreated control group (P=0.025 and P<0.001, respectively). 
However, i.p. treatment was less toxic than i.v. treatment. Tumor-specific targeting 
of S. typhimurium A1-R was confirmed with bacterial culture from tumors and various 
organs and tumor or organ colony formation after i.v. or i.p. injection. Selective tumor 
targeting was most effective with i.p. administration. The results of the present study 
show S. typhimurium A1-R has promising clinical potential for disseminated ovarian 
cancer, especially via i.p. administration.
IntroductIon 
Ovarian cancer is a leading cause of cancer-related 
death among women in the U.S. with 22,000 being 
diagnosed and 14,000 deaths each year [1]. If the cancer 
has distantly spread from the ovary, the 5-year survival 
rate is 27% [2, 3] since platinum-based chemotherapy, 
which is first-line, for ovarian cancer with peritoneal 
dissemination [4], has low efficacy. 
For more than 200 years cancers have been observed 
to regress following acute bacterial infections, mostly 
streptococcal [5]. In the late 19th and early 20th centuries. 
Coley infected cancer patients with Streptococcus 
pyrogenes and later treated the patients with extracts of the 
bacteria, which became known as Coley’s toxins. Coley 
often had very good results with both the bacteria and the 
toxins [6]. 
Recently, there has been intense interest to 
develop bacterial therapy of cancer [6, 7]. The barriers 
in tumors for standard therapy such as hypoxia, acidic 
pH, disorganized vascular architecture, are beneficial for 
bacteria to target cancer [7]. 
One approach to bacterial therapy of cancer is 
to use anaerobic bacteria such as Bifidobacterium [8] 
and Clostridium [9] which replicate in necrotic areas of 
tumors. Anaerobic bacteria cannot grow in oxic viable 
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tumor tissue, which restricts their efficacy. In addition, 
obligate anaerobic bacteria may be limited to intratumor 
(i.t.) injection which would preclude their use for 
metastatic cancer. 
Recently a human patient with metastatic 
leiomyosarcoma was treated by i.t. injection of 
Clostridium novyi (C. novyi)-NT spores which reduced 
the tumor within and surrounding the bone [10]. 
Salmonella typhimurium, which is a facultative 
anaerobe, was previously attenuated with purine and 
other auxotrophic mutations, as well as lipid A-modified 
(msbB), and termed VNP20009 [11], VNP20009 was 
tested in a Phase I clinical trial on patients with metastatic 
melanoma and renal cell carcinoma [12]. 
Another strain of S. typhimurium, A1-R, has been 
developed by our laboratory and has increased antitumor 
efficacy compared to VNP20009 [13]. S. typhimurium 
A1-R is auxotrophic for Leu-Arg which prevents it from 
mounting a continuous infection in normal tissues. A1-R 
has no other attenuating mutations as does VNP20009 and, 
therefore, has higher tumor virulence. A1-R was able to 
eradicate primary and metastatic tumors in monotherapy 
in nude mouse models of prostate, breast, lung and 
pancreatic cancer, as well as sarcoma and glioma [14-
22]. Tumors with a high degree of vascularity were more 
sensitive to A1-R, and vascular destruction appears to play 
a role in A1-R antitumor efficacy [23, 24]. 
S. typhimurium A1-R can target chemo-resistant 
pancreatic cancer stem-like cells [25] and pancreatic 
cancer patient-derived PDOX orthotopic xenographs [26]. 
In a recent study, we demonstrate that A1-R inhibits 
tumor growth, dissemination, and metastasis and extends 
survival in mouse models of aggressive human ovarian 
cancer [27]. 
The present study demonstrates S. typhimurium 
A1-R is highly effective for disseminated ovarian cancer, 
especially when administered i.p.
results And dIscussIon 
S. typhimurium A1-r inhibits ovarian cancer cell 
proliferation in vitro in a dose-dependent manner
S. typhimurium A1-R was effective on SKOV3-GFP 
ovarian cancer cells in vitro. The number of SKOV3-GFP 
colonies was 649.3 ± 39.6 in the control group; 597.3 ± 
30.4 when treated with 1×107 CFU/ml S. typhimurium 
A1-R; 396.7 ± 25.0 when treated with 1×108 CFU/ml 
S. typhimurium A1-R; and 247.0 ± 12.7 when treated 
with 1×109 CFU/ml of S. typhimurium A1-R (Fig. 1a,b). 
SKOV3-GFP colony areas were 30.5 ± 2.9(% of dish 
area) in control group; 14.1 ± 0.8(% of dish area) when 
treated with 1×107 CFU/ml of S. typhimurium A1-R; 7.17 
± 0.5(% of dish area) when treated with 1×108 CFU/ml 
of S. typhimurium A1-R; and 2.30 ± 0.9(% of dish area) 
when treated with 1×109 CFU/ml of S. typhimurium A1-R 
(Fig. 1c). These results indicate that S. typhimurium A1-R 
inhibits proliferation of SKOV3-GFP cells in a dose- 
dependent manner.
establishment of the nude-mouse model of human 
ovarian cancer peritoneal dissemination
Two weeks after i.p. implantation of SKOV3-GFP 
cells (5×106), tumor dissemination was confirmed in all 10 
mice on the peritoneum visualized with GFP imaging (Fig. 
2). Tumors were confirmed at sacrifice and laparotomy. 
Disseminated tumors growing in the abdominal cavity led 
to animal death at approximately 40 days (Fig. 2).
S. typhimurium A1-r therapy extended the 
survival period of the peritoneal dissemination 
model
Nude mice with disseminated ovarian cancer were 
divided into three groups: untreated control; treatment 
with i.v. injection of S. typhimurium A1-R (5×107 CFU); 
and treatment with i.p. injection of S. typhimurium A1-R 
(5×107 CFU). Median survival in the control group was 35 
days; i.v. -treated group, 47 days; and i.p.-treated group 60 
days. One mouse in the i.v.-treated group and three mice in 
the i.p.-treated group survived to day 90. Treatment with 
i.v. or i.p. injection of S. typhimurium A1-R significantly 
prolonged the survival period compared with the control 
group (p = 0.025 and p < 0.001, respectively, Fig. 3c, d).
The body weight was compared among the 
three groups to assess the toxicity of bacterial therapy. 
Maximum body weight loss was 8.8% in the i.v. group 
on day 1, and 5.8% in the i.p group on day 2. The body 
weight recovered by day 5 in the i.p. group. These results 
indicate that i.p. bacterial therapy is more effective 
for disseminated ovarian cancer and less toxic than i.v. 
injection.
S. typhimurium A1-r administrated i.p. is 
eliminated from normal tissues
Ten nude mice without tumor were also treated by 
i.v. or i.p. injection of S. typhimurium A1-R (Fig. 4a). 
Twenty-four hours after bacterial injection, blood, ascites, 
liver, spleen and tumor were harvested from each mouse 
and seeded on LB-Agar dishes. After 24-hour culture, S. 
typhimurium A1-R colony formation was assessed with 
fluorescence imaging (OV100, Olympus, Japan) (Fig. 
4b, c). In mice without tumors, no S. typhimurium A1-R 
was detected when treated i.p.. In contrast, spleens in two 
mice treated with i.v. injection of S. typhimurium A1-R 
had colony formation. In mice with disseminated ovarian 
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Figure 2: nude mouse model of disseminated ovarian cancer. a. Within seven days after i.p. injection of SKOV3-GFP cells 
(5×106 cells in 250 μl PBS), disseminated tumors appeared, visualized by fluorescence imaging (Bar: 1 cm). b. Fluorescence imaging via 
the peritoneum on day 14. c. Representative intraperitoneal imaging at death. (Bar: 1 cm) BF: bright field.
Figure 1: Efficacy of S.typhimurium A1-r on ovarian cancer cells in vitro. a. Clonogenic assays were performed. b. SKOV3-
GFP colony number after S. typhimurium A1-R treatment. c. SKOV3-GFP colony area after S. typhimurium A1-R treatment. *P < 0.05, **P 
< 0.01 compared with the control group.
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Figure 3: S. typhimurium A1-r treatment of disseminated ovarian cancer. a. Study design for comparing the route of administration 
of S. typhimurium A1-R. b. Treatment schedule. On day 0, SKOV3-GFP cells were (5×106 ) injected into the peritoneal cavity in 45 nude 
mice. On day 7, tumor formation was confirmed in 44 mice. Mice were divided into three groups. S. typhimurium A1-R (5×107  CFU) was 
injected i.v. or i.p. once a week starting from day 7. To assess the toxicity of A1-R treatment, the body weight of all mice was measured on 
days 0, 1, 2, 5, 7, 9, 14. c. Survival curves of treated and control groups of mice. The survival period of the treated mice was significantly 
prolonged compared with the untreated control group (P = 0.025 in i.v. group; P < 0.001 in i.p. group). d. Representative time-course images 
of treated and control mice (bright-field [BF] and GFP imaging, Bar: 1 cm). 
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cancer, i.p. injection resulted in higher amounts of S. 
typhimurium A1-R in the tumors. In contrast, i.v. injection 
of S. typhimurium resulted in bacterial colonies grown 
from blood, liver, and spleen as well as tumor (Table 1). 
This result indicates that S. typhimurium A1-R can be 
eliminated from tissues in mice without tumors and S. 
typhimurium A1-R administrated i.p. had greater tumor 
specificity then when administered i.v.
Our results demonstrate that i.p. administration of S. 
typhimurium A1-R has higher antitumor efficacy and less 
toxicity in nude mouse models of disseminated ovarian 
cancer, demonstrating clinical potential for this currently 
highly treatment-resistant disease.
The tumor-targeting of disseminated ovarian cancer 
strategy developed in the present report could also be used 
with previously-developed tumor targeting strategies [28-
35].
Figure 4: selective tumor-targeting of S. typhimurium A1-r after different routes of treatment. a. Study design. Twenty mice 
were divided into two groups: injection of SKOV3-GFP cells (5×106 cells) or PBS into the peritoneal cavity. Half of the mice in each group 
were treated with i.v. or i.p. injection of S. typhimurium A1-R. b. Schedule of the study. Fourteen days after injection, S. typhimurium 
A1-R (5 × 107 CFU) were injected i.v. or i.p. into each of five mice with or without tumor. Twenty-four hours after treatment, all mice 
were sacrificed. Blood, ascites, liver, spleen, and tumors were harvested for culture of S. typhimurium A1-R. Each tissue was seeded on 
LB-Agar medium with serial dilution in triplicate. Colony formation was assessed after 24 hours with fluorescence imaging (OV-100). c. 
Representative negative and positive findings of S. typhimurium A1-R colony formation. 
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MAterIAls And Methods
cell line and culture conditions
The SKOV3-GFP [36] human ovarian cancer cell 
line (AntiCancer, Inc., San Diego, CA) was used for this 
study. Cells were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine 
serum (Sigma-Aldrich). All media were supplemented 
with penicillin and streptomycin (Gibco-BRL). Cells were 
cultured at 37°C with 95% air and 5% CO2.
Mice
Athymic nude mice (nu/nu) (AntiCancer, Inc.), 7 
weeks, were used. Mice were kept in a barrier facility 
under HEPA filtration. Mice were fed with autoclaved 
laboratory rodent diet. All animal studies were conducted 
in accordance with the principles and procedures outlined 
in the NIH guide for the Care and Use of Laboratory 
Animals under assurance number A3873-1.
Preparation of S. typhimurium A1-r for treatment
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer Inc., San Diego, CA, USA) were grown 
overnight in LB medium and then diluted 1:10 in LB 
medium. Bacteria were harvested at late-log phase, 
washed with PBS, and then diluted in PBS. Bacteria were 
then ready for injection in mice [16]. 
clonogenic assay
SKOV3-GFP cells were grown in 6-well plates to a 
density of approximately 1×103 cells/well. S. typhimurium 
A1-R GFP were diluted in cell culture medium and added 
to the cancer cells at either 1×107, 1×108 or 1×109 CFU/ml 
and incubated for 60 min at 37°C. The cells were rinsed 
and cultured in medium containing gentamycin sulfate 
(20 μg/ml) to kill external, but not internal, bacteria. After 
seven days culture, cancer-cell colonies were fixed with 
ethanol and then stained with crystal violet. The number 
of colonies and the ratio of colony areas were assessed 
by ImageJ (National Institutes of Health, Bethesda, MD).
dissemination model of ovarian cancer in nude 
mice
To establish a mouse model of ovarian cancer 
dissemination in the peritoneal cavity, SKOV3-GFP 
cells (5×106) suspended in 250 μl PBS were injected 
into the peritoneal cavity in nude mice. Two weeks 
after implantation, tumor formation were assessed with 
fluorescence imaging and laparotomy. The Olympus 
OV100 Small Animal Imaging System (Olympus, Tokyo, 
Japan) was used for whole body imaging in live mice [37].
S. typhimurium A1-r therapy of disseminated 
ovarian cancer in nude mice
Seven days after the implantation of SKOV3-GFP 
cells as described above, intra-abdominal tumor formation 
was confirmed with fluorescence imaging in 44 mice. The 
44 mice were divided into three groups (Fig. 3a):
1) Treatment with i.v. injection of S. typhimurium 
A1-R (n = 15).
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S. typhimurium A1-R (5×107 CFU) in 100 μl PBS 
was injected i.v. once every seven days starting seven days 
post-implantation. 
2) Treatment with i.p. injection of S. typhimurium 
A1-R (n = 15).
S. typhimurium A1-R (5×107 CFU) in 100 μl PBS 
was injected i.p. once every seven days, starting seven 
days after cell injection. 
3) No treatment group (n = 14).
The overall survival time of each group was 
determined. The body weight of all mice was measured 
at day 0, 1, 2, 5, 7, 9, 14 in order to assess toxicity of S. 
typhimurium A1-R therapy. 
tumor selectivity of S. typhimurium A1-r
SKOV3-GFP (5×106 cells) were injected i.p. in 10 
nude mice. Fourteen days after the implantation, five mice 
were treated with i.v. injection of S. typhimurium A1-R 
(5×107 CFU) and another five mice were treated with i.p. 
injection of S. typhimurium A1-R (5×107 CFU). Ten nude 
mice without tumor were also treated with S. typhimurium 
A1-R i.v. or i.p., five mice each (Fig. 4a). Twenty-four 
hours after bacterial administration, blood, ascites, liver, 
spleen and tumor were harvested and seeded in LB-
Agar dishes. After 24-hour culture, S. typhimurium A1-R 
colony formation was assessed with fluorescence imaging 
(OV100, Olympus, Japan) (Fig. 4b, c).
statistical analysis
Data comparisons between two groups were 
assessed using the Student’s t-test. When more than two 
groups were assessed, analysis of variance (ANOVA) 
was used. The Kaplan-Meier method was used for 
survival analysis. The log-rank test was used for statistical 
significance of the difference between the two groups. 
Differences were considered significant when P < 0.05. 
Data are expressed as mean ± standard error (SE). 
Statistical analyses were performed with EZR (Saitama 
Medical Center, Jichi Medical University).
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